Cargando…

Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics

Mostrar otras versiones (1)

Cystic fibrosis (CF) is one of the most prevalent lethal genetic diseases with over 2000 identified mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Pharmacological chaperones such as Lumacaftor (VX-809), Tezacaftor (VX-661) and Elexacaftor (VX-445) treat mutation-in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Minsoo, McDonald, Eli Fritz, Sabusap, Carleen Mae P., Timalsina, Bibek, Joshi, Disha, Hong, Jeong S., Rab, Andras, Sorscher, Eric J., Plate, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915750/ https://www.ncbi.nlm.nih.gov/pubmed/36778339 http://dx.doi.org/10.1101/2023.02.04.527134

Ejemplares similares

Elexacaftor/VX-445–mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics
por: Kim, Minsoo, et al.
Publicado: (2023)

Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants
por: McDonald, Eli Fritz, et al.
Publicado: (2022)

Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination
por: Kleinfelder, Karina, et al.
Publicado: (2023)

The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue
por: Sabusap, Carleen Mae, et al.
Publicado: (2021)

VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level
por: Cui, Guiying, et al.
Publicado: (2019)

Structural Comparative Modeling of Multi-Domain F508del CFTR
por: McDonald, Eli Fritz, et al.
Publicado: (2022)

Targeted Gene Insertion for Functional CFTR Restoration in Airway Epithelium
por: Barillà, Cristina, et al.
Publicado: (2022)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators
por: Wang, Wei, et al.
Publicado: (2016)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2
por: Bongiorno, Roberta, et al.
Publicado: (2023)

Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
por: Yeh, Han-I, et al.
Publicado: (2019)

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis
por: Pankow, Sandra, et al.
Publicado: (2015)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium
por: Braccia, Clarissa, et al.
Publicado: (2022)

Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
por: Matos, Ana M., et al.
Publicado: (2021)

Vx-809, a CFTR Corrector, Acts through a General Mechanism of Protein Folding and on the Inflammatory Process
por: Pecoraro, Michela, et al.
Publicado: (2023)

Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis
por: Lim, Sang Hyun, et al.
Publicado: (2018)

Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies
por: Davies, Jonathan P., et al.
Publicado: (2020)

Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
por: Stanton, Bruce A., et al.
Publicado: (2015)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
por: Tsai, Alice, et al.
Publicado: (2020)

Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR
por: Farinha, Carlos M, et al.
Publicado: (2015)

Differential CFTR-Interactome Proximity Labeling Procedures Identify Enrichment in Multiple SLC Transporters
por: Chevalier, Benoît, et al.
Publicado: (2022)

PHL8/445: Internet Courses for Cancer Patients
por: Forbriger, A
Publicado: (1999)

ZNF445 is a primary regulator of genomic imprinting
por: Takahashi, Nozomi, et al.
Publicado: (2019)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

CFTR interactome mapping using the mammalian membrane two‐hybrid high‐throughput screening system
por: Lim, Sang Hyun, et al.
Publicado: (2022)

445 Inability of Medical Students to Use of Three Types of Inhaler
por: Jeong, Jae-Won
Publicado: (2012)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

THE DETECTION OF A VIRAL INTERFERING SUBSTANCE IN THE SHOPE PAPILLOMA AND THE Vx7 AND Vx2 CARCINOMAS
por: Langston, Deborah Pavan, et al.
Publicado: (1967)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022)

Thyroglobulin Interactome Profiling Defines Altered Proteostasis Topology Associated With Thyroid Dyshormonogenesis
por: Wright, Madison T., et al.
Publicado: (2020)

Microsurgery for intracranial arteriovenous malformation: Long-term outcomes in 445 patients
por: Ren, Qingqing, et al.
Publicado: (2017)

Evaluation of the Seroprevalence of Infectious Diseases in 2,445 in vitro Fertilization Cycles
por: Anjos, João Guilherme Grassi dos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d0rddgbr84k65vb0m23t8udsf6